Compare BOLT & DKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOLT | DKI |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | Hong Kong |
| Employees | N/A | 19 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 10.0M |
| IPO Year | 2021 | N/A |
| Metric | BOLT | DKI |
|---|---|---|
| Price | $3.97 | $4.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $34.00 | N/A |
| AVG Volume (30 Days) | ★ 16.1K | 6.4K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,695,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $133.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.07 | N/A |
| 52 Week Low | $3.75 | $0.28 |
| 52 Week High | $7.20 | $11.80 |
| Indicator | BOLT | DKI |
|---|---|---|
| Relative Strength Index (RSI) | 47.76 | 36.29 |
| Support Level | $3.90 | $3.96 |
| Resistance Level | $4.46 | $5.14 |
| Average True Range (ATR) | 0.24 | 0.19 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 39.10 | 2.35 |
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.